Regeneron Pharmaceuticals, Inc. (Regeneron), a fully integrated biotechnology company, invents, develops, manufactures, and commercializes medicines for people with serious diseases.
The company’s products and product candidates in development are d…
Analysis
Bargain bin
Regeneron Pharmaceuticals, Inc. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.
On valuation, the picture is fair. The owner-earnings multiple stands at 15.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 3% a year, against analyst forecasts of 11%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 2026100
100
2026
All-time high
100
Jun 2026
All-time low
100
Jun 2026
Average rank
100
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
85
—
—
—
Price/Earnings
10
—
—
—
Price/Book
69
—
—
—
Dividend Yield
99
—
—
—
Value (overall)
98
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.